Development Genotype Licensing Protein 
Drug Discovery World
DECEMBER 12, 2023
KRRO-110 is an RNA editing oligonucleotide delivered to liver cells using clinically validated lipid nanoparticle (LNP) technology licensed from Genevant. Selecting a development candidate for our AATD program is an important milestone for Korro, but more importantly, for patients.
The Pharma Data
DECEMBER 9, 2020
Liebisch , Vigil Neuroscience is developing a pipeline of precision-based therapies to combat both rare and common neurodegenerative diseases by restoring the vigilance of microglia. Atlas cofounded, seeded and incubated Vigil, with pre-clinical stage assets in-licensed from Amgen Inc., Vigil Neuroscience. SciNeuro Pharmaceuticals.
Expert insights. Personalized for you.
52 
Let's personalize your content